Odalasvir

Odalasvir
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name Dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane- 12,42-diylbis{1H-benzimidazole-5,2-diyl[(2S,3aS,7aS)- octahydro-1H-indole-2,1-diyl][(2S)-3-methyl-1-oxobutan- 1,2-diyl]})biscarbamate;
CAS Number	1415119-52-6 ;
PubChem CID	71474517;
ChemSpider	34500837;
UNII	OVR52K7BDW;
Chemical and physical data
Formula	C60H72N8O6
Molar mass	1001.286 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1; Key:LSYBRGMTRKJATA-IVEWBXRVSA-N;

Odalasvir (INN,[1] previously known as ACH-3102)[2][3] is an investigational new drug in development for the treatment of hepatitis C.[4] It is an NS5A inhibitor.[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.[6][7][8] It is under development by Achillion Pharmaceuticals.

References

"International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73" (PDF). who.int. World Health Organization. p. 38. Retrieved 5 December 2015.
"Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. Retrieved 15 November 2015.
"Odalasvir". ChemIDplus.
Walker T (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas". Managed Healthcare Executive: 47. Retrieved March 12, 2016.
Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O (March 2014). "Hepatitis C virus NS5A inhibitors and drug resistance mutations". World Journal of Gastroenterology. 20 (11): 2902–12. doi:10.3748/wjg.v20.i11.2902. PMC 3961994. PMID 24659881.
"ACH-3102 resources". Achillion Pharmaceuticals. Winter 2011. Retrieved 1 May 2012.
"Achillion gets FDA incentives for hepatitis C drug". Associated Press. 15 May 2012.
Levin J (18–22 April 2012). Preclinical characteristics of ACH-3102. 47th Annual Meeting. Barcelona, Spain: European Association for the Study of the Liver.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.